This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Basu, S. Articles by Lahiri, A. Search for Related Content PubMed PubMed Citation Articles by Basu, S. Articles by Lahiri, A.

(Circulation. 1997;96:183-191.)
© 1997 American Heart Association, Inc.

Articles

Beneficial Effects of Intravenous and Oral Carvedilol Treatment in Acute Myocardial Infarction

A Placebo-Controlled, Randomized Trial

Sumit Basu, MBBS; Roxy Senior, MBBS; Usha Raval, HND; Reinhard van der Does, MD; Thomas Bruckner, BSc; ; Avijit Lahiri, MBBS, MSc

From the Department of Cardiology, Northwick Park Hospital and Institute of Medical Research, Harrow, UK.

Correspondence to Dr Avijit Lahiri, Department of Cardiology, Northwick Park Hospital and Institute of Medical Research, Watford Rd, Harrow, Middlesex HA1 3 UJ, UK.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background Evidence of efficacy and safety of ß-blockers after thrombolysis for acute myocardial infarction (AMI) is equivocal. Newer ß-blockers such as carvedilol have not been tested in this setting.

Methods and Results This study investigated the effects of acute (intravenous) and long-term (6 months, oral) treatment with carvedilol versus placebo in 151 consecutive patients with AMI. Exercise ECG, ambulatory monitoring, and two-dimensional echocardiography were performed before hospital discharge and at 3 and 6 months. All patients were followed up and cardiovascular events recorded. The Cox proportional hazards model was used to compare time from randomization with the occurrence of a cardiovascular event, and Kaplan-Meier survival curves were calculated. Carvedilol was found to be safe, and it significantly reduced cardiac events compared with placebo (18 on carvedilol and 31 on placebo, P<.02). Fifty-four patients had heart failure at study entry; 34 received carvedilol. There were no adverse effects of carvedilol therapy and no excess events in this subgroup. Carvedilol produced significant reductions in heart rate (P<.0001), blood pressure (P<.005) at rest, and rate-pressure product at peak exercise (P<.003), but exercise capacity was unchanged. Left ventricular ejection fraction was not altered significantly by carvedilol, but stroke volume was higher at pre–hospital discharge examination (63 versus 53 mL; P<.01). Diastolic filling of the left ventricle (E/A ratio) was also improved (1.2 versus 0.9; P<.001). In a subgroup with left ventricular ejection fraction <45% (n=49 patients; 24 on carvedilol and 25 on placebo), carvedilol showed attenuation of remodeling.

Conclusions Carvedilol was well tolerated and safe to use in patients immediately after AMI, including those with heart failure, and significantly improved outcome.

Key Words: myocardial infarction • thrombolysis • vasodilation • adrenergic beta antagonist

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The effect of early treatment with ß-blockers in reducing mortality and ischemic events after acute myocardial infarction (AMI) is well known. Trials with intravenous ß-blockers have shown reduction of early mortality by 13% when used within 24 hours of chest pain.^{1 2 3} Long-term treatment also has been shown to reduce both mortality and reinfarction.^{4 5} However, all these studies were conducted before the widespread use of thrombolysis and aspirin. One large-scale, randomized trial of intravenous versus oral ß-blockade in patients treated with thrombolytic drugs failed to show reduction in mortality but did show a reduction in ischemic events,⁶ while another showed increased adverse events in the group treated with intravenous atenolol.⁷ Furthermore, the negative inotropic effect of ß-blockers and their potential for aggravating heart failure have, in most cases, limited their use to patients who were not in heart failure at study entry.¹

Carvedilol is a unique multiple-action drug, a nonselective ß-blocker with additional vasodilating properties caused by ₁ blockade.⁸ It is an effective antianginal⁹ and antihypertensive agent.¹⁰ Previous studies have shown that carvedilol improves both idiopathic and ischemic congestive heart failure^{11 12} and confers beneficial effects in patients with left ventricular dysfunction.¹³ Furthermore, recent studies have shown a large mortality benefit (65%) after carvedilol therapy¹⁴ when added to conventional treatment for congestive heart failure. Additionally, carvedilol affects the lipid profile favorably.¹⁵ It has also been shown to be beneficial in renal dysfunction¹⁶ and significantly limit infarct size in animal models.¹⁷ Furthermore, it is a potent antioxidant and hence may reduce damage caused by free radical generation.¹⁸

Thrombolysis and antiplatelet therapy have significantly reduced mortality after AMI.^{19 20} Reperfusion of the occluded coronary artery produces myocardial salvage; however, the "salvaged" myocardium remains at risk of future ischemic events.^{19 21} A drug with the properties demonstrated by carvedilol and one that may be safely given intravenously to most patients, including those in moderately severe heart failure,²² may be ideally suited to reduce both acute and long-term complications after AMI.

The primary aim of the study was to compare a group of patients with proven myocardial infarction treated with carvedilol with a matched cohort on placebo with respect to the time of development of one of several cardiovascular end points. Secondary objectives included evaluation of the safety of the drug as judged by incidence and nature of side effects and hematologic, biochemical, and ECG screening as well as evaluation of efficacy as judged by exercise capacity, hemodynamics, and systolic and diastolic left ventricular function.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patient Selection
Patients admitted to the coronary care unit with typical signs and symptoms suggestive of AMI, ie, chest pain, ECG changes, and serum concentration of creatine kinase and MB isoform consistent with the diagnosis, were recruited to the study. Patients were subsequently withdrawn if the cardiac enzymes failed to show the typical pattern of acute myocardial necrosis. All patients gave informed consent, and the study was approved by the hospital ethics committee.

Exclusion Criteria
Patients were excluded if they were already on - or ß-blockers and calcium antagonists or had contraindications to - or ß-blockers; if they were in Killip class IV heart failure or cardiogenic shock (classes I to III were not excluded); or if they had severe bradycardia (heart rate <45 bpm), hypotension (systolic blood pressure <90 mm Hg), second- to third-degree heart block, left bundle-branch block, severe valvular disease, insulin-dependent diabetes, renal failure (creatine >159 µmol/L), known malignancy, or other severe disease or pregnancy.

Study Design
The study was designed as a single-center, double-blind, randomized, parallel-group, placebo-controlled study with stratification for location of infarction (anterior or inferior) and thrombolysis or no thrombolysis.

Dosing and Concomitant Therapy
All patients were given aspirin and had subcutaneous heparin for 3 days. The decision regarding use of thrombolysis was left entirely to the judgment of the admitting physician. Subsequently, within 24 hours of chest pain, patients were injected intravenously with 2.5 mg of carvedilol or placebo over 15 minutes. This was followed by an oral dose of 6.25 mg carvedilol or matching placebo at 4 hours after injection and then 6.25 mg BID for 2 days. The dose was increased to 12.5 mg BID at day 3 and then maintained at 12.5 mg to 25 mg BID for the duration of the study (6 months) or until a cardiovascular end point had been reached when the drug was stopped (there was no down titration). Dose titration was performed at day 14, with carvedilol being increased to 25 mg BID if blood pressure was >120/95 mm Hg and heart rate >55 bpm. End points were defined as cardiac death; reinfarction; unstable angina; heart failure; emergency revascularization; ventricular arrhythmia requiring intervention; stroke; and additional cardiovascular therapy other than sublingual nitrates for angina, diuretics for hypertension, or continuation of preexisting ACE inhibitors, digitalis, or antiarrhythmics. However, initiation of therapy with these latter three drugs after recruitment to the study, for clinical reasons, was also considered an end point. ACE inhibitors were not routinely administered for asymptomatic left ventricular dysfunction.

Study Procedures
All patients were assessed clinically at study entry for presence or absence of heart failure on the basis of Killip criteria. They had 12-lead ECGs daily for 3 days, at hospital discharge, and at every visit (days 14, 42, 84, and 168). Exercise ECG, echocardiography, and 24-hour ambulatory ECG monitoring were performed at predischarge examination and then at days 84 and 168 (study completion). Cardiac enzymes were estimated daily for 3 days. Biochemistry and hematology were tested at admission and days 42 and 168.

Follow-up
All patients were followed up after discharge from the hospital at days 14, 42, 84, and 168 (study completion). Subsequently, all patients recruited were reviewed every 3 months (including those who dropped out before study completion) until the last patient had completed 6 months, and adverse cardiac events were documented.

Twenty-Four–Hour Ambulatory Monitoring
This was carried out with the use of a Marquette Electronics series 8500 recorder, utilizing leads CM5 and CC5. Analysis was performed with the use of a Marquette Electronics Series 8000 analyzer. Tapes were analyzed for cardiac arrhythmias, ventricular ectopic counts, and hourly averaged heart rate.

Exercise ECG
Treadmill exercise testing was performed on a computer-assisted ECG system (CASE 12, Marquette Electronics Inc). A 13-lead system (12 lead + CM₅) and the modified Bruce protocol were used. The ECG was continuously monitored throughout exercise and for 6 minutes after exercise termination. Blood pressure was recorded manually every 3 minutes, and ST-segment change was measured at J+60 ms. Exercise tests were used to assess angina, ST-segment changes, exercise capacity, and rate-pressure product (heart rate times systolic blood pressure).

Echocardiography
Two-dimensional, M-mode, and Doppler echocardiography was performed with the use of a digitized system (Ultramark 9, Advance Technology Laboratories). Parasternal long- and short-axis and apical four- and two-chamber views were obtained. Doppler recordings of left ventricular inflow (peak early [E] and late [A]) velocities and outflow velocities were made from the apical four-chamber view. Left ventricular volumes, ejection fraction (Simpson's technique), and E/A ratio were calculated according to methods described in detail elsewhere and validated in our laboratory.^{23 24} Systolic wall thickening and endocardial wall motion at rest were scored as grade 0, normal; grade 1, mild hypokinesia; grade 2, severe hypokinesia; grade 3, akinesia; and grade 4, dyskinesia. This was graded using a 13-segment left ventricular model. Global wall motion score index was calculated by adding the wall motion score and then dividing it by the number of left ventricular segments (n=13). Wall motion score at the site of myocardial infarction was also calculated by summing the wall motion score at the infarct site.

Statistical Analysis
Sample size calculations for the primary outcome variable, time from randomization to development of any cardiovascular end point, were based on two-sided tests with a significance level of 5% and a power of 80%. It was calculated that 144 patients (72 in each group) would be required to demonstrate a 20% difference between the groups.

Primary analysis was performed to compare the time from randomization with development of any one of the cardiovascular end points on an intention-to-treat basis in all patients with confirmed myocardial infarction and who had been given at least one dose of trial medication. The logistic regression test was applied before survival analysis was performed to identify factors that could have been related to the occurrence of cardiovascular end points. The factors analyzed were treatment group, sex, race, age, and site of infarction; previous history of diabetes, hyperlipidemia, hypertension, and smoking; and time from onset of pain to thrombolysis and to infusion of carvedilol or placebo. This showed that only the treatment group had a value of P<.05 and hence, thereafter, primary efficacy analysis was performed in the intention-to-treat population with the use of the Cox proportional hazards model, considering treatment as the only factor. Wilcoxon and log rank tests were also performed in the same cohort. Separate Cox analyses were also performed for "hard" end points—death and reinfarction— and also after exclusion of revascularization and need for nonpermitted cardiovascular medication. Additionally, a subgroup analysis was performed for patients who had clinical evidence of heart failure at study entry to assess the safety and efficacy of carvedilol in this group. Furthermore, the effects of drug therapy in patients with poor left ventricular function (ie, ejection fraction <45%) were also assessed by ANOVA and Fisher's exact test. Secondary variables were analyzed with descriptive statistics. Wilcoxon U tests were calculated in the case of continuous variables to detect differences between groups. A value of P<.05 was considered significant. The continuous variables are expressed as mean (standard deviations in parentheses).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Demography
Duration of the study was from February 1992 to September 1994. Of the 416 patients screened, 265 were excluded. The main reasons for exclusion were preexisting therapy with either ß-blockers (n=41) or calcium blockers (n=45), elevated creatinine (n=28), delays in admission over 24 hours (n=28), poor mobility or inability to perform exercise for any other reason (n=22), declined consent (n=17), chronic obstructive airway disease (n=15), Killip class IV heart failure or death before recruitment (n=18), and patient residence outside our catchment area (n=11). The remaining 40 had miscellaneous reasons such as malignancy, left bundle-branch block, insulin-dependent diabetes, and advanced heart block.

A total of 151 patients were randomized to either carvedilol (n=77) or placebo (n=74); 146 were analyzed for efficacy on an intention-to-treat basis. Four patients (2 from each group) were excluded because they were found not to have sustained a myocardial infarction on the basis of the criteria used; 1 patient was found to have renal failure and was not given study medication. Demographic data for the 146 patients are given in Table 1. There were no differences between the carvedilol and placebo groups; neither were there any differences between the two groups with respect to previous drug therapy.

View this table: [in this window] [in a new window]   Table 1. Patient Characteristics

Concomitant Therapy
Most patients (95%) underwent thrombolysis with streptokinase; 7 patients received tissue plasminogen activator. All patients received aspirin, 97% received heparin, and 80% received either oral or intravenous nitrates. Diuretics were allowed during the acute phase but later only for the control of hypertension. There were no differences between the groups regarding concomitant medication. No patients were on calcium channel blockers, long-acting nitrates, or ACE inhibitors during the course of the study, since clinical requirement for these drugs was a designated end point. The majority (91%) of patients on carvedilol were on 12.5 mg BID during the study.

Cardiac End Points
Treatment Period
There were significantly fewer serious cardiac events in the group treated with carvedilol (n=18) compared with placebo (n=31) (P<.02; Cox proportional hazards model, Wilcoxon and log rank tests) despite the small number of patients studied (n=146). The breakdown of events is shown in Fig 1. Even after excluding the soft end points of revascularization and requirement for nonpermitted cardiovascular medication, the effect of carvedilol therapy remained significant, with 24 events on placebo compared with 14 events on carvedilol (P<.03). This study was not powered to detect differences between hard events; however, there was a trend toward benefit, with 11 deaths or reinfarctions on placebo compared with 6 on carvedilol—a 45% reduction (P=.12). Of the 12 patients (n=8 on placebo and 4 on carvedilol) who had reinfarction, 11 occurred in the original infarct territory.

View larger version (16K): [in this window] [in a new window]   Figure 1. Incidence and distribution of adverse cardiac events on carvedilol and placebo during the period on randomized therapy (6 months). CABG indicates coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty.

In the subgroup presenting with acute heart failure at study entry, 34 were on carvedilol and 20 on placebo. None of these patients had any adverse events related to intravenous infusion of the drug, and there was no excess of cardiac events with carvedilol during either the in-hospital phase (6 events on carvedilol, 4 on placebo) or during subsequent follow-up (13 events on carvedilol compared with 9 events on placebo) (P=NS for both). Requirement for intravenous nitrates or diuretics during the acute phase did not differ between the two groups. Additionally, in this subgroup with acute heart failure, patients on carvedilol had significantly greater left ventricular ejection fraction: 45% (10) versus 35% (12), P=.005; lower end-systolic volume: 62 (23) mL versus 80 (30) mL, P=.03; lower wall motion score index: 0.85 (0.47) versus 1.46 (0.62), P<.001; and lower wall motion score at infarct site: 7.7 (3.3) versus 12.2 (4.3), P<.001, compared with placebo, before discharge.

Kaplan-Meier survival curves for carvedilol and placebo groups are shown in Fig 2. It is clear that separation between the two groups begins as early as the in-hospital (within day 7) phase, and the lines continue to separate throughout the treatment phase (6 months).

View larger version (12K): [in this window] [in a new window]   Figure 2. Kaplan-Meier curves showing the effect of treatment with carvedilol on event-free survival during the period on randomized therapy (6 months).

Follow-up Period
After withdrawal of treatment at 6 months, 10 patients who had been on carvedilol had cardiovascular events. Interestingly, the majority (8) of the events were ischemic (unstable angina or reinfarction), and 7 of the 10 patients had been started on treatment with either atenolol (n=4), diltiazem (n=2), nicardipine (n=3), long-acting nitrates (n=4), or a combination at study completion. The Kaplan-Meier survival curves for the full duration of the study are shown in Fig 3; it is evident that the curves start to converge after carvedilol was withdrawn and that the difference between the groups no longer remains statistically significant (P>.05) despite the use of other standard anti-ischemic drugs.

View larger version (13K): [in this window] [in a new window]   Figure 3. Kaplan-Meier curves showing the effect of treatment with carvedilol and withdrawal of drug on event-free survival (31 months).

Electrocardiography
Carvedilol produced a significant reduction in 24-hour heart rate trend compared with placebo (Fig 4) during all visits. Cardiac arrhythmia was not significantly reduced by carvedilol, but there was wide variability and this may account for the lack of difference. There were no differences between the groups at any visit regarding exercise time or ST-segment change (Table 2). However, patients on carvedilol had a lower heart rate, blood pressure, and rate-pressure product at peak exercise and at maximal comparable workloads at all visits (Fig 5).

View larger version (16K): [in this window] [in a new window]   Figure 4. Twenty-four–hour ambulatory heart rate profile (hourly means) of patients on carvedilol and placebo at predischarge examination demonstrates significant reduction of heart rate.

View this table: [in this window] [in a new window]   Table 2. Exercise Times, ST-Segment Changes, and Ejection Fractions on Carvedilol and Placebo

View larger version (11K): [in this window] [in a new window]   Figure 5. Rate-pressure product at peak exercise is shown for carvedilol and placebo at predischarge examination, day 84, and day 168 (study end). Box represents first and third quartiles; horizontal line is the median, and dot represents the mean. Whisker plots represent extremes of the data.

Echocardiography
There were no differences in left ventricular ejection fraction (Table 2) between the groups at any visit, but stroke volume values were greater in patients on carvedilol (P<.01) (Fig 6). The diastolic function parameter, E/A ratio, was significantly greater on carvedilol than placebo at predischarge examination (P<.001), demonstrating improved left ventricular filling (Fig 7).

View larger version (11K): [in this window] [in a new window]   Figure 6. Stroke volume (mL) is shown for predischarge examination, day 84, and day 168 (study end). Data are represented as in Fig 5.

View larger version (13K): [in this window] [in a new window]   Figure 7. Peak E wave–to–A wave velocity ratio is shown at predischarge examination, day 84, and study end. Data are represented as in Fig 5.

Subgroup With Ventricular Dysfunction
There were 49 patients with left ventricular ejection fraction <45% (24 on carvedilol and 25 on placebo) (Table 3). Despite similar infarct size and hemodynamic status at study entry, the left ventricular end-systolic and diastolic volumes were smaller in the carvedilol group; 79 (22) mL and 121 (29) mL, respectively, compared with placebo; and 91 (32) mL and 137 (38) mL, respectively, at predischarge examination. At 3 months, carvedilol significantly reduced both end-systolic (P<.01) and end-diastolic (P=.01) volumes; 74 (30) mL and 122 (34) mL, respectively, compared with placebo; and 100 (45) mL and 148 (53) mL, respectively (Fig 8). Carvedilol improved left ventricular ejection fraction from 35 (8)% at predischarge examination to 39 (9)% at 3 months compared with placebo 32 (7)% and 34 (10)%, respectively, but the difference was not significant (P=.06). Wall motion score at the site of infarction was 11.6 (3.4) in the carvedilol group compared with 12.7 (3.2) in the placebo group at predischarge examination. By 3 months, there was a significant improvement with carvedilol, 8.3 (4.3) compared with placebo, 11.4 (5) (P=.02). Similarly, global wall motion score index was also improved by carvedilol (P=.03) (Fig 8).

View this table: [in this window] [in a new window]   Table 3. Patient Characteristics (Patients With Ejection Fraction <45%)

View larger version (15K): [in this window] [in a new window]   Figure 8. Effect of carvedilol on remodeling in patients with left ventricular ejection fraction <45% in comparison to placebo. EDV indicates end-diastolic volume (mL); ESV, end-systolic volume (mL); RWMS, regional wall motion score; and WMSI, global wall motion score index.

Serious cardiac events (death, reinfarction, unstable angina, congestive heart failure, and ventricular tachycardia) were reduced significantly (n=5 on carvedilol, n=13 on placebo, P=.04) (Fig 9).

View larger version (17K): [in this window] [in a new window]   Figure 9. Incidence and distribution of adverse cardiac events on carvedilol and placebo in patients with left ventricular ejection fraction <45% during the period of randomized therapy (6 months). CHF indicates congestive heart failure; MI, myocardial infarction; UA, unstable angina; and VT, ventricular tachycardia.

Safety Data
Hematologic and biochemical evaluations were performed three times during the study, and there were no differences between the groups. There were also no differences between the groups regarding creatine kinase levels. There were no serious adverse events related to intravenous administration of carvedilol. Adverse events requiring withdrawal unrelated to cardiac end points were similar (ie, 4 on carvedilol and 3 on placebo). Dizziness was slightly more frequent on carvedilol (6.5% compared with 1.4%) but did not cause withdrawal from the study.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In canine models, pretreatment with ß-blocker has been shown to redistribute blood flow to the endocardium, which is usually more jeopardized by the process of ischemia.²⁵ ß-Blockers reduce rate-pressure product, thus reducing oxygen requirement, and may limit infarct size. The progress of infarction, from vessel occlusion to myocardial necrosis, is usually complete within a few hours of onset of symptoms²⁶ and hence any intervention aimed at limiting infarct size and preventing events needs to be initiated early.

In the prethrombolytic era, a large number of trials of ß-blockers, used early, intravenously, and over longer periods, showed benefits such as improvement in chest pain and reduction in infarction size²⁷ as well as reduction in mortality.^{1 2 3 4 5}

However, there has been a quantum change in the management of myocardial infarction since the majority of these studies were performed. The widespread use of thrombolytic therapy and aspirin has greatly reduced mortality. It is not known whether the benefits obtained previously with ß-blockers are still likely to be present. Indeed, in the TIMI II-B study there was no difference in 6-day mortality between the immediate intravenous metoprolol and delayed oral metroprolol groups, but a reduction in nonfatal reinfarction and chest pain was observed.⁶ However, results from the GUSTO study appear to indicate that in patients given atenolol intravenously there was an increased incidence of shock, congestive heart failure, myocardial ischemia, and requirement for pacing.⁷ These factors have clearly restricted the widespread use of the standard ß-blocker therapy after AMI. In the GISSI-3 study,²⁸ just 31% of patients were prescribed ß-blockers after myocardial infarction, while in the AIRE study,²⁹ the figure was even lower (22%). While the use of thrombolysis has greatly reduced mortality,^{19 20} the salvaged myocardium in the infarct-related artery territory is likely to remain at higher risk of future events. An area of such viable but ischemic myocardium may be the cause of angina, myocardial infarction, arrhythmia, and sudden death.^{19 21} Thus, in the thrombolytic era it may be more difficult to show mortality benefits, and one must investigate the incidence of serious ischemic complications in the postinfarction phase.

Carvedilol has demonstrated potent anti-ischemic,⁹ cardioprotective,¹⁷ and antioxidant¹⁸ properties. Its beneficial effects in left ventricular dysfunction are manifested in both idiopathic and ischemic heart failure,^{12 13} unlike metoprolol³⁰ and bisoprolol,³¹ which have shown benefits only in dilated cardiomyopathy. This may be due to the effect of carvedilol in improving regional wall motion abnormality in patients with ischemic left ventricular dysfunction.³² This is likely to result in functional improvement in patients with hibernating myocardium, which is often present in patients with ischemic cardiomyopathy³³ and after myocardial infarction with thrombolysis.³⁴ Alternatively, the "protective" action of carvedilol may actually lie in its effect of reducing neurohormonal activation.³⁵

Carvedilol significantly reduced double product as the result of its combined - and ß-blocking activity; it also improved stroke volume and left ventricular diastolic function (A/E ratio) but not exercise duration or left ventricular ejection fraction. However, these patients had relatively good left ventricular function and exercise capacity, and at each stage there were fewer patients in the placebo group because of larger dropouts after events. Hence, patient selection, with clinically better patients continuing in the placebo group, may have caused this lack of difference.

Despite the small number of patients and a dose of carvedilol at the lower end of the therapeutic range, there was a potent effect in reducing serious cardiac events during the treatment phase (42%). The main reduction was of the ischemic events, ie, reinfarction, unstable angina, and urgent revascularization, thus demonstrating the effect of the drug on ischemic and jeopardized myocardium after infarction. In this context, it is of note that of the 12 patients with reinfarction (8 on placebo and 4 on carvedilol), 11 occurred at the site of the original infarction. The reduction of "hard events" was 45%, but in view of the small numbers, this failed to reach statistical significance (P=.12). Since introduction of softer events such as revascularization and nonpermitted cardiovascular medication may dilute the results, analysis was also performed with the exclusion of these end points. However, the study still remained statistically significant, with a 42% reduction in events (P<.03).

Patients with heart failure at study entry were unevenly distributed (34 on carvedilol, 20 on placebo), and this may have a bearing on the apparent failure of the drug to reduce the number of patients having heart failure as an end point. It is also worth noting that despite the large number of patients with heart failure at entry, intravenous carvedilol was well tolerated, with no dropouts after infusion. Furthermore, the patients on carvedilol derived benefit in terms of left ventricular ejection fraction improvement and decreased wall motion abnormality. The majority of earlier studies of ß-blockers in AMI have excluded such patients.¹ Treatment with intravenous carvedilol in patients with severe chronic congestive heart failure has shown that carvedilol reduces filling pressure.²² This finding is likely to be of influence in the design of future trials of carvedilol in high-risk patients with higher grades of heart failure who may be safely included, thus expanding the therapeutic window to patients who are likely to derive the greatest benefit.

Remodeling, associated with AMI, is characterized by deleterious alterations of left ventricular size, shape, and thickness involving the infarcted and noninfarcted segments of the myocardium,³⁶ and this is affected by infarct size, infarct healing, and loading characteristics (left ventricular distending pressure, inotropic state, heart rate, and neuroendocrine activation).^{37 38} Progressive remodeling is associated with worsening left ventricular function and poor prognosis.^{36 39} Acute reperfusion (eg, thrombolysis) and ACE inhibitors reduce remodeling.^{37 40} Preliminary studies have shown that carvedilol may reverse left ventricular wall motion abnormality in patients with ischemic heart disease with myocardial infarction.³² Furthermore, this drug produces significant reduction in neurohormonal activation in congestive heart failure.⁴¹ Our data in the subgroup of patients with ejection fraction <45% after AMI show that carvedilol may have an effect on attenuation of remodeling by decreasing left ventricular size and wall motion abnormality at the infarct site. These effects are associated with a 65% reduction in serious cardiac events.

After stopping carvedilol, 10 patients who had been on the drug subsequently had cardiac events, 8 of which were ischemic (unstable angina and reinfarction). None of the events occurred immediately after withdrawal; thus, a "rebound" phenomenon was absent. Furthermore, 6 patients had events despite treatment with atenolol or diltiazem. Finally, carvedilol had an excellent safety profile.

Conclusions
Carvedilol is a novel, multiple-action vasodilating ß- and ₁-blocker with additional properties of cardioprotection and free radical suppression. This study demonstrates that carvedilol is safe to use after AMI with or without associated heart failure. Carvedilol also has the potential to reduce ischemic events and mortality, but larger trials are required to further elucidate its beneficial effects.

	Acknowledgments

 
The study was supported by educational grants from the NPH Cardiac Research Fund, Harrow, UK, and Boehringer Mannheim GmbH, Mannheim, Germany. We would like to acknowledge the assistance of Christopher Kinsey, Rita Hamill, Jenny Ralph, Minoo Shah, and Catherine Belling. We would like to thank Caroline Dore and the nursing staff of the coronary care unit. We also would like to acknowledge the late Dr Edward B. Raftery.

Received October 2, 1996; revision received December 16, 1996; accepted January 1, 1997.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Yusuf S, Peto R, Lewis J, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis. 1985;17:335-371.
   
2. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo controlled international trial. Eur Heart J. 1985;6:199-226.[Abstract/Free Full Text]
   
3. ISIS-I (First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-I. Lancet. 1986;2:57-66.[Medline] [Order article via Infotrieve]
   
4. Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.[Abstract]
   
5. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA. 1982;247:1707-1714.[Abstract]
   
6. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, Zaret BL, Wackers FJT, Braunwald E, TIMI Investigators. Immediate versus deferred ß-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation. 1991;83:422-437.[Abstract/Free Full Text]
   
7. Brener SJ, Cox JL, Pfisterer ME, Armstrong PW, Califf RM, Topol EJ, GUSTO Investigators. The potential for unexpected hazard of intravenous beta-blockade for acute myocardial infarction: results from the GUSTO trial. J Am Coll Cardiol. 1995;(suppl 5A):901-903.
   
8. Sponer G, Bartsch W, Strein K, Muller-Beckman B, Boehm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 1987;9:317-327.[Medline] [Order article via Infotrieve]
   
9. Rodrigues EA, Lahiri A, Hughes LO, Kholi RS, Whittington JR, Raftery EB. Anti-anginal efficacy of carvedilol, a new beta-blocking drug with vasodilating activity. Am J Cardiol. 1986;58:916-921.[Medline] [Order article via Infotrieve]
   
10. Heber ME, Brigden GS, Caruana MP, Lahiri A, Raftery EB. Carvedilol for systemic hypertension. Am J Cardiol. 1987;59:400-405.[Medline] [Order article via Infotrieve]
    
11. DasGupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1990;66:1118-1123.[Medline] [Order article via Infotrieve]
    
12. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomised study. J Am Coll Cardiol. 1995;25:1225-1231.
    
13. Lahiri A, Rodrigues EA, Al-Khawaja I, Raftery EB. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris. Am J Cardiol. 1987;59:769-774.[Medline] [Order article via Infotrieve]
    
14. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.[Abstract/Free Full Text]
    
15. Hauf-Zachariou U, Widmann L, Zuelsdorf B, Hennig M, Lang PD. A double blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol. 1993;45:95-100.[Medline] [Order article via Infotrieve]
    
16. Nakamoto H, Suzuki H, Katsumata H, Ohishi A, Saruta T, Sakaguchi H. Effects of carvedilol on renal function and blood pressure in three-fifth nephrectomized spontaneously hypertensive rats loaded with high salt. Drugs. 1988;336(suppl 6):160-164.
    
17. Ruffolo RR Jr, Boyle DA, Brooks DP, Feuerstein GZ, Venuti RP, Lukas MA, Poste G. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc Drugs Rev. 1992;10:127-157.
    
18. Kramer JH, Weglicki WB. A hydroxylated analog of the ß-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts. Free Radic Biol Med. 1996;21:813-825.[Medline] [Order article via Infotrieve]
    
19. Gruppo Italiano per lo Studio della Streptochinasi nell'infarto Miocardico. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2:871-875.[Medline] [Order article via Infotrieve]
    
20. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS 2. Lancet. 1988;2:349-360.[Medline] [Order article via Infotrieve]
    
21. Simoons ML, Vos J, Tijssen JGP, Vermeer F, Verheugt FWA, Krauss XH, Cats VM. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Inter University Cardiology Institute of the Netherlands. J Am Coll Cardiol. 1989;14:1609-1615.[Abstract]
    
22. DasGupta P, Broadhurst P, Lahiri A. The effects of intravenous carvedilol, a new multiple action vasodilatory ß-blocker in congestive heart failure. J Cardiovasc Pharmacol. 1991;18(suppl 4):S12-S16.
    
23. Senior R, Buchner-Moell D, Raftery EB, Lahiri A. Potent hemodynamic effects of Bimakalim, a new potassium channel opener, in humans. J Cardiovasc Pharmacol. 1993;22:717-721.[Medline] [Order article via Infotrieve]
    
24. Senior R, Sridhara BS, Basu S, Henley M, Handler CE, Raftery EB, Lahiri A. Comparison of radionuclide ventriculography and 2D echocardiography for the measurement of left ventricular ejection fraction following acute myocardial infarction. Eur Heart J. 1994;15:1235-1239.[Abstract/Free Full Text]
    
25. Buck JD, Hardman HF, Warltier DC, Gross GJ. Changes in ischemic blood flow distribution and dynamic severity of coronary stenoses induced by ß-blockade in canine heart. Circulation. 1981;64:708-715.[Abstract/Free Full Text]
    
26. Yusuf S, Lopez R, Madison A, Sleight P. Variability of electrocardiographic and enzyme evolution of myocardial infarction in man. Br Heart J. 1981;45:271-280.[Abstract/Free Full Text]
    
27. Yusuf S, Sleight P, Rosi PRF, Ramsdale D, Peto R, Furze L, Sterry H, Pearson M, Motwani R, Parish S, Gray R, Bennet D, Bray C. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous ß-blockade in suspected acute myocardial infarction. Circulation. 1983;67(suppl I):I-32-I-41.
    
28. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-1122.[Medline] [Order article via Infotrieve]
    
29. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.[Medline] [Order article via Infotrieve]
    
30. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441-1446.[Medline] [Order article via Infotrieve]
    
31. CIBIS Investigators and Committees. A randomised trial of ß-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.[Abstract/Free Full Text]
    
32. Lahiri A, Rodrigues EA, DasGupta P, Jain D, Van der Does R, Raftery EB. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease. Z Kardiol. 1989;78(suppl 3):21-27.
    
33. Senior R, Glenville B, Basu S, Sridhara BS, Anagnostou E, Stanbridge R, Edmondson SJ, Handler CE, Raftery EB, Lahiri A. Dobutamine echocardiography and Tl-201 imaging predict functional improvement following revascularisation in severe ischaemic left ventricular dysfunction. Br Heart J. 1995;74:358-364.[Abstract/Free Full Text]
    
34. Basu S, Sridhara B, Senior R, Duncker DM, Raval U, Handler CE, Raftery EB, Lahiri A. Role of thallium-201 reinjection in the assessment of myocardial viability following myocardial infarction. Br Heart J. 1993;69(suppl):61.
    
35. Lahiri A. Neurohumoral mechanisms in congestive heart failure and the role of drugs with multiple actions: a review of carvedilol. Am J Ther. 1996;3:237-247.[Medline] [Order article via Infotrieve]
    
36. McKay RG, Pfeffer MA, Pasternak RC. Left ventricular remodeling following myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74:693-702.[Abstract/Free Full Text]
    
37. Marino P, Zanolla L, Zaerdini P. Effect of streptokinase on left ventricular modelling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. J Am Coll Cardiol. 1989;14:1149-1158.[Abstract]
    
38. Vaughan D, Lamas G, Pfeffer MA. Role of left ventricular dysfunction in selective neurohormonal activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol. 1990;66:529-532.[Medline] [Order article via Infotrieve]
    
39. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation. 1990;81:1161-1172.[Abstract/Free Full Text]
    
40. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.[Abstract]
    
41. Ruffolo RR, Gellai M, Hieble JP, Willete RN, Nicholas AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38:82-88.
    

This article has been cited by other articles:

				D. C. Parrish, K. Gritman, D. M. Van Winkle, W. R. Woodward, M. Bader, and B. A. Habecker Postinfarct sympathetic hyperactivity differentially stimulates expression of tyrosine hydroxylase and norepinephrine transporter Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H99 - H106. [Abstract] [Full Text] [PDF]

				M. Cucherat Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials Eur. Heart J., December 2, 2007; 28(24): 3012 - 3019. [Abstract] [Full Text] [PDF]

				G I W Galasko, S Basu, A Lahiri, and R Senior Is echocardiography a valid tool to screen for left ventricular systolic dysfunction in chronic survivors of acute myocardial infarction? A comparison with radionuclide ventriculography Heart, December 1, 2004; 90(12): 1422 - 1426. [Abstract] [Full Text] [PDF]

				R. A. Kloner and S. H. Rezkalla Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J. Am. Coll. Cardiol., July 21, 2004; 44(2): 276 - 286. [Abstract] [Full Text] [PDF]

				R. N. Doughty, G. A. Whalley, H. A. Walsh, G. D. Gamble, J. Lopez-Sendon, N. Sharpe, and on behalf of the CAPRICORN Echo Substudy Investiga Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction: The CAPRICORN Echo Substudy Circulation, January 20, 2004; 109(2): 201 - 206. [Abstract] [Full Text] [PDF]

				J. J. Cai, D. A. Morgan, W. G. Haynes, J. B. Martins, and H.-C. Lee alpha 2-Adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2606 - H2611. [Abstract] [Full Text] [PDF]

				J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]

				M. G. St. J. Sutton and N. Sharpe Left Ventricular Remodeling After Myocardial Infarction : Pathophysiology and Therapy Circulation, June 27, 2000; 101(25): 2981 - 2988. [Full Text] [PDF]

				J. N. Cohn, R. Ferrari, N. Sharpe, and on Behalf of an International Forum on Cardiac Rem Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J. Am. Coll. Cardiol., March 1, 2000; 35(3): 569 - 582. [Abstract] [Full Text] [PDF]

				M. R. Bristow {beta}-Adrenergic Receptor Blockade in Chronic Heart Failure Circulation, February 8, 2000; 101(5): 558 - 569. [Full Text] [PDF]

				F. Romeo, D. Li, M. Shi, and J. L Mehta Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway Cardiovasc Res, February 1, 2000; 45(3): 788 - 794. [Abstract] [Full Text] [PDF]

				S. G. Crysant Carvedilol Arch Fam Med, July 1, 1999; 8(4): 295 - 295. [Full Text] [PDF]

				W. H. Frishman Carvedilol N. Engl. J. Med., December 10, 1998; 339(24): 1759 - 1765. [Full Text] [PDF]

				H. Yaoita, A. Sakabe, K. Maehara, and Y. Maruyama Different Effects of Carvedilol, Metoprolol, and Propranolol on Left Ventricular Remodeling After Coronary Stenosis or After Permanent Coronary Occlusion in Rats Circulation, February 26, 2002; 105(8): 975 - 980. [Abstract] [Full Text] [PDF]

This Article Abstract Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend